Clinical data from CML patient samples
| Patient no. . | WBCs, 109/L . | BM metaphases . | LTC-ICs (Ph+/total) . | Cells used . | % CD34+ cells before enrichment . | % CD34+ cells after enrichment . |
|---|---|---|---|---|---|---|
| CP1 | 116 | 46XY, t(9;22), 27/27 | 7/8 | BM | 5.5 | 86 |
| CP2 | 172 | 46XX, t(9;22), 25/25 | 9/9 | BM | 12.4 | 99 |
| CP3 | 740 | 46XY, t(9;22), 25/25 | 35/35 | BM | 7.3 | 92 |
| CP4 | 560 | 46XY, t(9;22), 29/29 | 18/18 | BM | 5.2 | 79 |
| CP5 | 240 | 46XX, t(9;22), 25/25 | 4/4 | BM | 21.2 | 98 |
| CP6 | 125 | 46XY, t(9;22), 21/21 | 12/12 | Blood | 6.8 | 92 |
| CP7 | 275 | 46XY, t(9;22), 25/25 | 8/8 | BM | 26.7 | 97 |
| CP8 | 145 | 46XX, t(9;22), 22/22 | 16/16 | BM | 5.3 | 96 |
| CP9 | 242 | 46XX, t(9;22), 30/30 | 10/10 | Blood | 7.8 | 95 |
| CP10 | 223 | 46XX, t(9;22), 28/28 | 10/12 | BM | 14.7 | 92 |
| CP11 | 354 | 46XX, t(9;22), 32/32 | 18/18 | BM | 22.5 | 98 |
| CP12 | 144 | 46XY, t(9;22), 44/45 | 22/22 | BM | 25.8 | 96 |
| CP13 | 645 | 46XX, t(9;22), 25/25 | 10/10 | BM | 15.6 | 91 |
| CP14 | 531 | 46XX, t(9;22), 30/30 | 13/13 | BM | 21.3 | 92 |
| CP15 | 232 | 46XX, t(9;22), 23/23 | 10/10 | BM | 10.9 | 95 |
| CP16* | 573 | 46XX, t(9;22), 21/26 | 30/35 | BM | 22.3 | 99 |
| CP17* | 640 | 46XX, t(9;22), 22/24 | 35/42 | BM | 27.5 | 99 |
| CP18* | 442 | 46XX, t(9;22), 25/28 | 21/25 | BM | 26.5 | 99 |
| BC1 | 675 | 46XY, t(9;22), 42/42 | 29/29 | BM | 15.8 | 91 |
| BC2 | 580 | 46XY, t(9;22), 35/35 | 32/32 | Blood | 13.3 | 95 |
| BC3 | 575 | 46XY, t(9;22), 22/22 | 15/15 | BM | 9.4 | 92 |
| BC4 | 450 | 46XY, t(9;22), 35/35 | 25/25 | BM | 23.2 | 88 |
| BC5 | 425 | 46XY, t(9;22), 30/30 | 35/35 | BM | 28.5 | 96 |
| Patient no. . | WBCs, 109/L . | BM metaphases . | LTC-ICs (Ph+/total) . | Cells used . | % CD34+ cells before enrichment . | % CD34+ cells after enrichment . |
|---|---|---|---|---|---|---|
| CP1 | 116 | 46XY, t(9;22), 27/27 | 7/8 | BM | 5.5 | 86 |
| CP2 | 172 | 46XX, t(9;22), 25/25 | 9/9 | BM | 12.4 | 99 |
| CP3 | 740 | 46XY, t(9;22), 25/25 | 35/35 | BM | 7.3 | 92 |
| CP4 | 560 | 46XY, t(9;22), 29/29 | 18/18 | BM | 5.2 | 79 |
| CP5 | 240 | 46XX, t(9;22), 25/25 | 4/4 | BM | 21.2 | 98 |
| CP6 | 125 | 46XY, t(9;22), 21/21 | 12/12 | Blood | 6.8 | 92 |
| CP7 | 275 | 46XY, t(9;22), 25/25 | 8/8 | BM | 26.7 | 97 |
| CP8 | 145 | 46XX, t(9;22), 22/22 | 16/16 | BM | 5.3 | 96 |
| CP9 | 242 | 46XX, t(9;22), 30/30 | 10/10 | Blood | 7.8 | 95 |
| CP10 | 223 | 46XX, t(9;22), 28/28 | 10/12 | BM | 14.7 | 92 |
| CP11 | 354 | 46XX, t(9;22), 32/32 | 18/18 | BM | 22.5 | 98 |
| CP12 | 144 | 46XY, t(9;22), 44/45 | 22/22 | BM | 25.8 | 96 |
| CP13 | 645 | 46XX, t(9;22), 25/25 | 10/10 | BM | 15.6 | 91 |
| CP14 | 531 | 46XX, t(9;22), 30/30 | 13/13 | BM | 21.3 | 92 |
| CP15 | 232 | 46XX, t(9;22), 23/23 | 10/10 | BM | 10.9 | 95 |
| CP16* | 573 | 46XX, t(9;22), 21/26 | 30/35 | BM | 22.3 | 99 |
| CP17* | 640 | 46XX, t(9;22), 22/24 | 35/42 | BM | 27.5 | 99 |
| CP18* | 442 | 46XX, t(9;22), 25/28 | 21/25 | BM | 26.5 | 99 |
| BC1 | 675 | 46XY, t(9;22), 42/42 | 29/29 | BM | 15.8 | 91 |
| BC2 | 580 | 46XY, t(9;22), 35/35 | 32/32 | Blood | 13.3 | 95 |
| BC3 | 575 | 46XY, t(9;22), 22/22 | 15/15 | BM | 9.4 | 92 |
| BC4 | 450 | 46XY, t(9;22), 35/35 | 25/25 | BM | 23.2 | 88 |
| BC5 | 425 | 46XY, t(9;22), 30/30 | 35/35 | BM | 28.5 | 96 |
Numbers after the karyotype indicate the numbers of metaphases with that karyotype of the total number analyzed. All CML patients in CP were collected at diagnosis before therapy. BC samples with at least 70% of blasts were used. Percentages of CD34+ cells before and after enrichment were also indicative of the efficiency of cell selection.
CP indicates chronic phase; BC, blast crisis; WBC, white blood cell count at sampling; BM, bone marrow; LTC-IC, long-term-culture initiating-cells; and Ph+, Philadelphia chromosome positive.
Selected CML CP patients from whom CD34+CD38− cells were isolated and analyzed by D-FISH after LTC-IC experiments.